Published in Ann Rheum Dis on May 14, 2007
Mouth Handicap in Systemic Sclerosis Questionnaire (MHISS) in Turkish | NCT04273386
The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology (Oxford) (2014) 1.48
The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis (SSc) patients. Rheumatol Int (2011) 0.94
Orofacial manifestations of systemic sclerosis. Br Dent J (2016) 0.89
The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial. Rheumatol Int (2010) 0.88
Factors associated with gingival inflammation among adults with systemic sclerosis. Int J Dent Hyg (2013) 0.79
Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. PLoS One (2011) 0.78
The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. Rheumatology (Oxford) (2014) 0.78
Translation, cross-cultural adaptation, and validation of the Mouth Handicap in Systemic Sclerosis questionnaire (MHISS) into the Dutch language. Clin Rheumatol (2013) 0.77
In systemic sclerosis, anxiety and depression assessed by hospital anxiety depression scale are independently associated with disability and psychological factors. Biomed Res Int (2013) 0.76
Efficacy of Autologous Microfat Graft on Facial Handicap in Systemic Sclerosis Patients. Plast Reconstr Surg Glob Open (2016) 0.75
Review of orofacial considerations of systemic sclerosis or scleroderma with report of analysis of 3 cases. Indian J Dent (2016) 0.75
Improvement of Microstomia in Scleroderma after Carbon Dioxide Laser Treatment. Case Rep Dermatol (2016) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Criteria for the classification of early systemic sclerosis. J Rheumatol (2001) 5.39
Relation of sample size to the stability of component patterns. Psychol Bull (1988) 4.09
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum (1997) 2.21
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res (1991) 1.78
Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum (2007) 1.75
Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil (1997) 1.62
Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum (2004) 1.29
Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol (1996) 1.27
Algo-functional assessment of knee osteoarthritis: comparison of the test-retest reliability and construct validity of the WOMAC and Lequesne indexes. Osteoarthritis Cartilage (2002) 1.20
Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum (2006) 1.14
[Measuring agreement between 2 observers: a quantitative case]. Rev Epidemiol Sante Publique (1984) 1.13
Sense of coherence as a determinant of the oral health-related quality of life: a national study in Finnish adults. Eur J Oral Sci (2005) 0.98
Concurrent validity of the Health Assessment Questionnaire Disability Index in Scleroderma. Arthritis Care Res (1995) 0.98
New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev (2003) 0.96
Sjogren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) (2006) 0.92
Reliability, validity, and sensitivity to change of the Cochin hand functional disability scale in hand osteoarthritis. Osteoarthritis Cartilage (2001) 0.88
The ability of the Cochin rheumatoid arthritis hand functional scale to detect change during the course of disease. Arthritis Care Res (2000) 0.86
[Systemic sclerosis: pathophysiology of a multifaceted disease]. Presse Med (2006) 0.83
[Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]. Rev Med Interne (2004) 0.82
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Cell-free translation of simian virus 40 early messenger RNA coding for viral T-antigen. Proc Natl Acad Sci U S A (1977) 6.57
EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2008) 4.88
Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J (1986) 4.24
Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature (1982) 3.74
Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum (2001) 3.67
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
A cytoplasmic particle bearing messenger ribonucleic acid in rat liver. J Mol Biol (1965) 3.28
Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci U S A (1982) 3.11
Cell-free translation of messenger RNA of simian virus 40: synthesis of the major capsid protein. Proc Natl Acad Sci U S A (1974) 3.04
Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells. FEBS Lett (1976) 2.92
Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A (1980) 2.88
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) (1996) 2.72
Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke (1993) 2.71
Structure of two forms of the interferon-induced (2'-5') oligo A synthetase of human cells based on cDNAs and gene sequences. EMBO J (1985) 2.47
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J (1983) 2.28
Interferon-induced 56,000 Mr protein and its mRNA in human cells: molecular cloning and partial sequence of the cDNA. Nucleic Acids Res (1983) 2.27
EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis (2008) 2.25
DNA probes specific for Entamoeba histolytica possessing pathogenic and nonpathogenic zymodemes. Infect Immun (1989) 2.22
Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. Nature (1988) 2.18
Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology (Oxford) (2006) 2.15
Post-transcriptional and translational controls of gene expression in eukaryotes. Annu Rev Biochem (1978) 2.06
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Role of the polyadenylate segment in the translation of globin messenger RNA in Xenopus oocytes. Proc Natl Acad Sci U S A (1974) 2.05
Role of protein factor in the functional binding of ribosomes to natural messenger RNA. J Mol Biol (1968) 2.05
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) (2007) 2.02
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut (1981) 2.00
Correlation between the antiviral effect of interferon treatment and the inhibition of in vitro mRNA translation in noninfected L cells. J Virol (1973) 2.00
Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. Proc Natl Acad Sci U S A (1978) 1.97
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) (2002) 1.96
Entamoeba histolytica ribosomal RNA genes are carried on palindromic circular DNA molecules. Mol Biochem Parasitol (1989) 1.92
A factor from E. coli required for the translation of natural messenger RNA. Biochem Biophys Res Commun (1966) 1.91
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris) (1982) 1.90
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum (2008) 1.90
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 1.88
Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin Infect Dis (1993) 1.88
Methodological approaches to shortening composite measurement scales. J Clin Epidemiol (1997) 1.85
Human chromosome 7 carries the beta 2 interferon gene. Proc Natl Acad Sci U S A (1986) 1.82
Interferon action: isolation of nuclease F, a translation inhibitor activated by interferon-induced (2'-5') oligo-isoadenylate. FEBS Lett (1978) 1.80
Translational discrimination of 'capped' and 'non-capped' mRNAS: inhibition of a series of chemical analogs of m7GpppX. FEBS Lett (1976) 1.77
Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis (1997) 1.75
Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol (1990) 1.74
Four different forms of interferon-induced 2',5'-oligo(A) synthetase identified by immunoblotting in human cells. J Biol Chem (1987) 1.74
Molecular cloning and sequence of partial cDNA for interferon-induced (2'-5')oligo(A) synthetase mRNA from human cells. Proc Natl Acad Sci U S A (1983) 1.73
Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol (1998) 1.73
Capacity of the clinical picture to characterize low back pain relieved by facet joint anesthesia. Proposed criteria to identify patients with painful facet joints. Spine (Phila Pa 1976) (1998) 1.71
Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J (1983) 1.71
Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res (1992) 1.70
Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology (1993) 1.64
Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest (1990) 1.64
Primary angiitis of the central nervous system. Clin Exp Rheumatol (2009) 1.64
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J (2011) 1.63
3' end structure of the human (2'-5') oligo A synthetase gene: prediction of two distinct proteins with cell type-specific expression. Nucleic Acids Res (1985) 1.63
Hiccup in adults: an overview. Eur Respir J (1993) 1.62
Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology (1990) 1.60
Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain (2008) 1.59
Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet (1981) 1.59
Interferon-responsive regulatory elements in the promoter of the human 2',5'-oligo(A) synthetase gene. Mol Cell Biol (1987) 1.59
Discrimination between messenger ribonucleic acids by a mammalian translation initiation factor. Proc Natl Acad Sci U S A (1973) 1.57
Kinetics of the induction of three translation-regulatory enzymes by interferon. Proc Natl Acad Sci U S A (1979) 1.56
Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group. Medicine (Baltimore) (2000) 1.50
Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg (1993) 1.50
Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci U S A (1988) 1.50
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol (2001) 1.49
Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol (1990) 1.48
The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood (1988) 1.47
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 1.47
Vasculitides secondary to infections. Clin Exp Rheumatol (2006) 1.47
Urinary trypsin inhibitory activity for the diagnosis of bacterial infection: a prospective study in 690 patients. Eur J Med (1992) 1.45
Virus-associated vasculitides. Rheumatology (Oxford) (1999) 1.45
The interferon-induced protein kinase PK-i from mouse L cells. J Biol Chem (1979) 1.45
In vitro translation of polyadenylic acid-free rabbit globin messenger RNA. J Mol Biol (1974) 1.45
Should aggregate scores of the Medical Outcomes Study 36-item Short Form Health Survey be used to assess quality of life in knee and hip osteoarthritis? A national survey in primary care. Osteoarthritis Cartilage (2007) 1.44
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
A human IFN-beta 1 gene deleted of promoter sequences upstream from the TATA box is controlled post-transcriptionally by dsRNA. Nucleic Acids Res (1984) 1.43
Intractable hiccups: the role of cerebral MR in cases without systemic cause. AJNR Am J Neuroradiol (1996) 1.41
Synthesis of human interferon beta 1 in Escherichia coli infected by a lambda phage recombinant containing a human genomic fragment. Eur J Biochem (1981) 1.41
Fear-avoidance beliefs about back pain in patients with subacute low back pain. Pain (2006) 1.41
Identification of the translation products of human fibroblast interferon mRNA in reticulocyte lysates. Eur J Biochem (1979) 1.40
An interferon-induced phosphodiesterase degrading (2'-5') oligoisoadenylate and the C-C-A terminus of tRNA. Proc Natl Acad Sci U S A (1979) 1.40
Eosinophilia-myalgia linked with L-tryptophan. Lancet (1990) 1.39
Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations. Vaccine (2009) 1.38
Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol (1994) 1.37
Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int (2006) 1.37
The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum (1993) 1.36
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax (2008) 1.35
Regulation of lymphocyte mitogenesis by (2'--5') oligo-isoadenylate. Nature (1980) 1.35
Antibodies to a cell-surface component coded by human chromosome 21 inhibit action of interferon. Nature (1976) 1.35
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis (2007) 1.35
A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol (1999) 1.34
The cell-free translation of SV40 messenger RNA. Cold Spring Harb Symp Quant Biol (1975) 1.34
A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J (1997) 1.33